Medicure (CVE:MPH) Sets New 52-Week High – Should You Buy?

Medicure Inc. (CVE:MPH) reached a new 52-week high during trading on Monday. The company traded as high as C$4.39 and last traded at C$4.30, with a volume of 5,901 shares traded. The stock had previously closed at C$4.25.

Medicure Trading Up 1.2%

The firm has a market capitalization of C$44.87 million, a price-to-earnings ratio of -5.97 and a beta of 0.98. The firm’s 50 day moving average is C$2.43 and its 200 day moving average is C$1.61. The company has a quick ratio of 1.28, a current ratio of 0.97 and a debt-to-equity ratio of 6.02.

Medicure Company Profile

Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.